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Pictorial Medical History (8)
T he control and outcome of rheumatoid arthritis (RA) and other con-nective tissue diseases have greatly improved with better under-standing of disease pathophysiology, and availability of effective and 
safe treatments. In this issue of the Journal, five rheumatologists will be 
writing on five therapeutic areas of rheumatology. Dr Lucia Chau and Dr Gavin 
Lee will give an overview of the basic and clinical aspects of two groups 
of commonly used medications, glucocorticoids and NSAIDs. With the wide-
spread use of biologic agents, you will encounter patients receiving these 
medications whether you are a rheumatologist or not. Dr Carrel Yu will highlight 
the risks and benefits of biologic use and Dr Temy Mok will summarize clinical 
use and toxicity monitoring of immunosuppressants in autoimmune disease 
for us in this issue. Last, but not least, Dr Samson Lee will review evidence for 
treatment options of a common symptom, ie, soft tissue pain. I hope you will 
find the articles of this issue both interesting and enjoyable to read. 
Dr lam Tat chung, Paul 
林達聰醫生
FRCP, FHKAM (Medicine)  
FRCPsych, FHKAM (Psychiatry)
President
editorial
Asclepius was so adept in the 
art of healing that he not only 
cured the sick, but could also 
raise people from the dead. 
In the picture, he can be seen 
reviving Hippolytus, another 
figure in Greek mythology, who 
died as he was thrown from his 
chariot in a man-made accident. 
(Eventually, Asclepius was killed 
by Zeus for upsetting the natural 
order of the Universe).
Dr lam Tat chung, Paul 
(林達聰醫生)
FRCP, FRCPsych, FHKAM (Medicine), 
FHKAM (Psychiatry)
Specialist in Psychiatry (Private Practice)
Honorary Clinical Assistant Professor, 
The University of Hong Kong
Dr chan Tak hin  
陳德顯醫生
FRCP, FHKAM (Medicine)
Editor
Asclepius reviving Hippolytus
Claude Lorraine, (1604–1682)
French Baroque Painter
Please read past issues of the Journal at: www.sophysicianshk.org
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Introduction
Glucocorticoid has revolutionized the treatment of countless medical conditions since its first use in the 
1950’s.1 It is particularly useful in rheuma-
tology, for example, in the treatment of 
systemic lupus erythematosus, inflam-
matory myositis, systemic vasculitis and 
various arthritides. In this article, the 
mechanisms of the therapeutic effects, 
as well as side effects, of glucocorticoids 
will be reviewed. Guidance on monitoring 
patients for adverse events will be dis-
cussed.
Mechanisms of anti-
inflammatory actions of 
glucocorticoids
The therapeutic effects of glucocorticoid 
result from its genomic and non-genomic 
effects. Genomic effects work through 
the glucocorticoid receptor (GR) and regu-
lation of gene transcription, while in non-
genomic pathways, gene transcription 
is not involved. The GR is present in 
the cytoplasm of virtually all cells as a 
hetero-oligomer consisting of the GR and 
heat-shock proteins. The binding of gluco-
corticoid to the GR leads to dissociation 
of the heat-shock proteins, resulting in 
transformational changes and activation 
of the GR (Figure 1). Subsequently, the 
activated GR-glucocorticoid complex 
passes through the nuclear membrane 
and forms homodimers. The homodimers 
regulate gene transcription via: (a) direct 
binding to glucocorticoid responsive 
elements of DNA, (b) interaction with 
other transcription factors, eg, nuclear 
factor, (NF)-κB and activating protein 
(AP)-1, and (c) modulation of stability of 
specific mRNA molecules.2 Examples 
of genes that are regulated by glucocor-
ticoid are shown in Table 1, and the end 
result is down-regulation of inflammatory 
products.
In contrast to genomic effects, 
non-genomic effects are more rapid. An 
example is the activation of endothelial 
nitric oxide synthetase (eNOS). 
Glucocorticoid stimulates the activity 
of phosphatidylinositol-3-hydroxykinase 
(PI3K) via a transcription-independent 
pathway in endothelial cells. Activated 
PI3K in turn phosphorylates protein kinase 
B (Akt) which subsequently leads to 
phosphorylation and activation of eNOS. 
Adverse effects of 
glucocorticoid therapy
Due to the pleiotropic effect of gluco-
corticoids, they have multiple potential 
glucocorticoid use in Rheumatology: 
mechanism of action, adverse effects and 
guidance on monitoring
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figure 1. genomic action of glucocorticoid receptor
table 1. genes regulated 
by glucocorticoid
Cytokines IL-1β, IL-6, IL-11, TNF-α, 
GM-CSF
Chemokines MCP-1, eotaxin, IL-8, RANTES, 
MIP-1α
Adhesion 
molecules
ICAM-1
Enzymes iNOS, COX-II, cPLA2α
Inhibitory 
proteins
Lc-1, IL-1RA type I, SPLI
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adverse effects,3 for example, skin and 
muscle atrophy, glaucoma, Cushing’s 
syndrome, diabetes mellitus and hyper-
tension. However, the likelihood of 
adverse effects varies between indi-
viduals; some can tolerate a moderate 
dose while others may have marked 
adverse effects on a minimal dose. In 
general, the duration, dosage, dosing 
regimen, specific glucocorticoid used, 
mode of application, and the individual’s 
susceptibility to adverse effects will 
determine the occurrence and severity 
of the adverse effects.3 Some of the 
adverse effects are discussed in detail 
below.
Avascular necrosis
Avascular necrosis (AVN, or osteone-
crosis) is the most feared adverse effect 
of glucocorticoids among Hong Kong 
residents due to its publicity in the 
SARS era. The pathophysiology linking 
glucocorticoid use and AVN is not fully 
understood, but it is postulated that 
glucocorticoids lead to the deposition 
of lipids in the femoral head, causing 
femoral hypertension and ischaemia.4 
Clinical studies have suggested a higher 
dose poses a higher risk for AVN than 
cumulative doses or duration of therapy. 
A dose of more than 20 mg/day of 
prednisolone is generally regarded as a 
threshold risk for AVN.5
osteoporosis
In patients receiving long term glucocor-
ticoids, 12% of bone is lost in the first 
few months, followed by a slower phase 
of 2–5% per year.6 A dose of as low as 
6 mg/day prednisolone for 6 months 
may cause significant bone loss.7 Steroid 
induced osteoporotic fracture is most 
common in vertebral bodies and ribs due 
to the loss of cancellous bone. The risk of 
fracture is also related to race, age, body 
weight, female sex, menopausal status, 
smoking history and nature of underlying 
illness.8
Gastrointestinal bleeding
Glucocorticoids are shown to increase 
gastric acid secretion, reduce gastric 
mucus, induce hyperplasia of gastrin and 
parietal cells and delay healing of ulcers 
in animal studies.3 In meta-analyses, 
the pooled relative risk for peptic ulcers 
ranged from 1.3 to 2.3. The risk is higher in 
patients taking concomitant nonsteroidal 
anti-inflammatory drugs (NSAIDs).9 The 
risk of upper gastrointestinal bleeding is 
also higher in patients receiving antico-
agulants and having a history of upper 
gastrointestinal bleeding.10
Guidance on the use 
of glucocorticoids
To promote a safer use of glucocor-
ticoids, the EUropean League against 
Arthritis and Rheumatism (EULAR) has 
published recommendations on the use 
of low-dose glucocorticoids (<7.5 mg/day 
prednisolone equivalent)11 and medium- to 
high-dose glucocorticoids (7.5–100 mg/day 
prednisolone equivalent)12 in rheumatic 
diseases. When low-dose glucocorticoid 
is used, it is recommended that clinicians 
monitor blood pressure, blood glucose, 
body weight, oedema, symptom of 
ischaemic heart disease and peptic ulcer. 
Monitoring of bone mineral density (BMD) 
by dual energy X-ray absorptiometry 
(DEXA) scan should be done according 
to local guidelines. For patients at risk of 
glaucoma (eg, family history of glaucoma, 
high myopia or diabetes), ophthalmologic 
evaluation should be done at the start of 
therapy. The EULAR recommendations 
for management of medium- to high-
dose glucocorticoid therapy are listed 
in detail in Table 2. In general, clinicians 
should monitor patients closely to ensure 
the lowest possible dose is used for the 
shortest duration, and carefully observe 
patients for adverse effects. Of note, cli-
nicians should offer prophylaxis for osteo-
porosis and patients should be instructed 
on prevention of acute cortisol insuffi-
ciency, particularly during severe inter-
current illnesses.
Conclusion
Glucocorticoids are useful and essential 
in the management of a broad variety of 
diseases. Its pleiotropic nature is linked 
to the wide variety of possible adverse 
effects. However, with judicious use and 
careful monitoring, the benefit of gluco-
corticoid therapy can be maximized with 
minimal increase in adverse outcomes.
table 2. the euLaR recommendations on the management of medium- to 
high-dose glucocorticoid therapy
1. Explain to patients (and their family and/or carers, including healthcare professionals) the aim of 
medium/high dose glucocorticoid treatment, and the potential risks associated with such therapy
2. Discuss measures to mitigate such risks, including diet, regular exercise and appropriate wound 
care
3. Patients with, or at risk of, glucocorticoid-induced osteoporosis should receive appropriate 
preventive/therapeutic interventions
4. Patients and the patients’ treatment teams should receive appropriate, practical advice on how to 
manage glucocorticoid-induced hypothalamic-pituitary-adrenal axis suppression
5. Provide an accessible resource to promote best practice in the management of patients using 
medium/high-dose glucocorticoids to general practitioners
6. Before starting medium/high dose glucocorticoid treatment consider comorbidities predisposing to 
adverse effects. These include diabetes, glucose intolerance, cardiovascular disease, peptic ulcer 
disease, recurrent infections, immunosuppression, (risk factors of) glaucoma and osteoporosis. 
Patients with these comorbidities require tight control to manage the risk/benefit ratio
7. Select the appropriate starting dose to achieve therapeutic response, taking into account the risk 
of undertreatment
8. Keep the requirement for continuing glucocorticoid treatment under constant review, and titrate 
the dose against therapeutic response, risk of undertreatment and development of adverse effects
9. All patients should have appropriate monitoring for clinically significant adverse effects. The 
treating physician should be aware of the possible occurrence of diabetes, hypertension, weight 
gain, infections, osteoporotic fractures, osteonecrosis, myopathy, eye problems, skin problems and 
neuropsychological adverse effects
A complete list of references can be downloaded from 
www.SOPHYSICIANSHK.org
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fibromyalgia
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Introduction
Fibromyalgia is a systemic disorder characterized by chronic widespread musculoskeletal pain, stiffness, 
fatigue and tenderness.1 It is often asso-
ciated with somatic symptoms, eg, 
allodynia and hyperalgesia1,2 and psycho-
logical disturbances, for example, poor 
sleep, anxiety, depressive symptoms and 
cognitive impairment. Physical exami-
nation shows increased tenderness 
at muscle and tendon insertion sites;3 
persistent pain and tenderness should 
continuously be present, for at least 3 
months, above and below the waist on 
both sides of the body.3
Diagnosis
Fibromyalgia presents a diagnostic 
challenge for physicians. Identification 
of fibromyalgia patients by the original 
1990 American College of Rheumatology 
(ACR) classification criteria required 
a specialized physical examination to 
quantify tender point count. The criteria 
required tenderness on pressure (tender 
points) in at least 11 of 18 specified sites, 
together with the presence of wide-
spread pain for diagnosis.3 Pain, on digital 
palpation, should be performed with an 
approximate force of 4 kg and must be 
present in at least 11 out of the following 
18 tender point sites:3
1. Occiput at the nuchal ridge: Bilateral, 
at the suboccipital muscle insertions
2. Low cervical: Bilateral, at the anterior 
aspects of the intertransverse spaces 
at C5–C7
3. Trapezius: Bilateral, at the midpoint of 
the upper border
4. Supraspinatus: Bilateral, at origins, 
above the scapula spine near the 
medial border
5. Second rib: Bilateral, at the second 
costochondral junctions, just lateral to 
the junctions on upper surfaces
6. Lareral epicondyle: Bilateral, 2 cm 
distal to the epicondyles
7. Gluteal: Bilateral, in upper outer 
quadrants of buttocks in anterior fold 
of muscle
8. Greater trochanter: Bilateral, posterior 
to the trochanteric prominence
9. Knee: Bilateral, at the medial fat pad 
proximal to the joint line
Unfortunately, in clinical practice, 
not all fibromyalgia patients experience 
all symptoms and have tender points. 
Although fibromyalgia is classified based 
on the presence of chronic widespread 
pain, the symptoms may be localized 
to the shoulders, necks, back and hips.4 
The utility of such diagnostic criteria is 
dependent on the clinical setting. The 
major obstacle in the diagnosis is the 
lack of objective physical or laboratory 
findings in fibromyalgia. It has not been 
widely adopted in primary care.5
The 2010 ACR diagnostic criteria 
allow for diagnosis by history, without 
specialized training.6 They constitute a 
more complex evaluation of fibromyalgia 
in patients and assess patients based on 
scores from both a widespread pain index 
(WPI) and a symptom severity (SS) scale.6 
The critical diagnostic variables are WPI 
and categorical SS scales for cognitive 
symptoms, unrefreshed sleep, fatigue, 
and number of somatic symptoms. The 
WPI quantifies the extent of bodily pain 
on a scale from 0–19 to measure pain or 
tenderness in 19 different body regions, 
including: shoulder girdle, hip, jaw, upper 
arm, upper leg, lower arm, lower leg, 
upper back, lower back, chest, neck and 
abdomen. The SS scale is comprised of 
two measurements, both the severity 
and the extent of symptoms. SS Scale 
measures problems with fatigue, cognitive 
dysfunction and unrefreshing sleep over 
the past week, each symptom is measured 
on a scale of 0–3 (0 = no problem, 1 = a 
slight or mild problem, 2 = a moderate or 
considerable problem and 3 = a severe, 
continuous, life-disturbing problem). The 
sum of these scores together with a 
measure of the physician’s impression 
of the number of somatic symptoms the 
patient has, on a scale of 0–3 (0 = no 
symptoms, 1 = a few symptoms, 2 = a 
moderate number of symptoms, and 3 = a 
great deal of symptoms), form an SS scale 
score of 0–12.
The SS scale and the WPI are 
combined to assess a case of fibro-
myalgia: WPI >7 and SS >5 or WPI 3–6 
and SS >9 are predictive of fibromyalgia. 
The symptoms should have been present 
for at least 3 months and other causes 
have been excluded.6 Fibromyalgia is a 
diagnosis of exclusion and patients must 
be thoroughly evaluated for the presence 
of other disorders that could be the 
cause of symptoms before a diagnosis 
of fibromyalgia is made.7 The ACR classi-
fication criteria constitute a simple clinical 
case definition of fibromyalgia and cor-
rectly classify 88.1% of cases, it does 
not require a physical or tender point 
examination. They are useful in the longi-
tudinal evaluation of patients with marked 
symptom variability.6
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Prevalence
Fibromyalgia is not uncommon; studies 
have estimated that the prevalence of 
fibromyalgia in the US general popu-
lation was 2–6.4% (3.5–7.7% in women 
and 0.5–4.9% in men).8,9 Branco et al. 
estimated the prevalence of fibromyalgia 
in Europe at 4.7% and White et al. 
estimated the prevalence of fibromyalgia 
at 3.3% in Ontario, Canada (4.9% women 
vs 1.6% men).10 In the general popu-
lation of Brazil, the prevalence of fibro-
myalgia has been estimated at 4.5%.11 
It is of note that fibromyalgia was rarely 
observed in China, with a prevalence of 
0.05%, which was distinctly lower than 
in reports from other parts of the world.12 
The prevalence of fibromyalgia in Hong 
Kong was estimated to be 0.82% [95% 
confidence interval (CI): 0.35%, 1.29%];13 
the prevalence of fibromyalgia in the 
Chinese population of Hong Kong was 
low but was similar to that of some other 
Western countries.11 
Mortality does not appear to be 
increased in patients with fibromyalgia, 
but the risk of death from suicide and 
accidents was seen to be increased.14 
A prospective study from Denmark 
followed patients with fibromyalgia for 
16 years and there was a reported 10-fold 
increased risk of death from suicide.15 A 
Swedish study of patient perspectives 
confirmed that fibromyalgia has a sig-
nificant negative impact on the quality 
of social and economic functions in 
patients’ lives and the average yearly cost 
for service utilization among fibromyalgia 
patients is $2,274.16
Pathophysiology
The aetiology of fibromyalgia is multifac-
torial and includes both environmental 
and genetic factors. The identification 
of central sensitization and abnormal 
central nociceptive processing in affected 
patients suggested that fibromyalgia 
was driven primarily by central sensiti-
zation and possibly through changes in 
several neuronal systems but not neces-
sarily reliant on peripheral processes.17 
Investigators have investigated different 
mechanisms in fibromyalgia, including 
studies of muscle, sleep physiology,18 
neurohormonal function19 and psycho-
logical status.20 Although the pathophys-
iology of fibromyalgia remains unknown, 
an increasing body of literature points 
towards central, rather than peripheral, 
mechanisms.21
Management
Fibromyalgia treatment is often difficult 
for both clinicians and patients because of 
the lack of a universally effective treatment 
or cure. Multidisciplinary approaches 
involving both physicians and psychia-
trists for management of fibromyalgia, 
include non-pharmacological approaches, 
for example, education, lifestyle changes 
and psychological treatment. Alongside 
pharmacological treatment, these can 
help the individual to achieve significant 
improvement.22 Models of pain behavior 
that interrelate biological, cognitive, emo-
tional and behavioural variables form 
the basis for cognitive-behavioural and 
operant-behavioural approaches that have 
been seen to be effective in pain man-
agement.23 Evidence-based recommen-
dations, including the European Congress 
of Rheumatology (EULAR) 2006 recom-
mendations24 and the 2005 American 
Pain Society (APS) guidelines, have been 
developed in fibromyalgia management.25 
Both guidelines recommend the use of 
acetaminophen, weak opiates, tricyclic 
antidepressants (TCAs) and other anti-
depressants as effective pharmacologic 
treatment options. 
Low-dose TCAs have proven 
short-term efficacy for pain control, 
improved sleep, and improved sense 
of well-being in fibromyalgia patients.26 
Selective serotonin reuptake inhibitors 
(SSRIs), including fluoxetine, cita-
lopram, escitalopram, fluvoxamine, 
paroxetine, and sertraline also improve 
symptoms in fibromyalgia. Treatment by 
dual serotonin/norepinephrine reuptake 
inhibitors (SNRIs), such as venlafaxine, 
milnacipram and duloxetine were also 
effective.27 Patients taking either SSRIs 
or SNRIs should be carefully monitored 
for worsening depression or emergence 
of suicidal thoughts.27 Unfortunately, 
NSAIDs,  including cyclo-oxygenase 
(COX-2) inhibitors, are ineffective against 
pain associated with fibromyalgia.27 The 
EULAR 2006 guidelines, recommended 
pregabalin as first-line pharmacologic 
treatment option for patients with fibro-
myalgia. Pregabalin was the first agent 
to receive a US Food and Drug Admin-
istration (FDA) approved indication for 
the treatment of fibromyalgia.24 EULAR 
guidelines also recommend the use of 
tropesitron, pramipexole and the APS 
guidelines specifically recommend anti-
depressants as first-line treatment.24,25 
Conclusion
There is evidence in support of fibro-
myalgia as a dimensional, or continuum, 
disorder. Treatment is difficult but both 
non-pharmacological and pharmaco-
logical approaches would be of benefit 
to a patient with fibromyalgia. Further 
studies to elucidate the pathogenesis of 
fibromyalgia and evidence-based studies 
on treatment response are essential. 
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Systemic lupus erythematosus (SLE) is an autoimmune disease that predominantly affects young 
women of child-bearing age. This disease 
is characterized by immune-complex 
mediated vasculitis and inflammation, 
leading to damage in various internal 
organs of the body. SLE is more prevalent 
among the Chinese population compared 
with Caucasians. It is estimated that 
around 0.07% of the population in 
Hong Kong suffers from this disease. 
SLE is a heterogeneous syndrome 
involving diverse organ manifestations 
and serological features, and the clinical 
course consists of exacerbations and 
remissions. Depending on the severity of 
organ involvement during the heightened 
disease activity at a “flare”, different 
treatment options are considered.
Articular and cutaneous mani-
festations are the most frequent pre-
sentations of lupus and are found in 
over 80% of patients. In the absence 
of systemic involvement, anti-malarials 
such as hydroxychloroquine (HCQ) are 
effective therapy for skin and joint mani-
festations. The recommended daily dose 
of HCQ is 200–400 mg. This drug is gen-
erally well tolerated with uncommon 
adverse effects including hyperpigmen-
tation of skin and bull’s eye retinopathy. 
Methotrexate (MTX), an immunosup-
pressive drug, better known as an anchor 
disease modifying anti-rheumatic drug 
(DMARD) in the treatment of rheumatoid 
arthritis, targets the metabolism of folic 
acid and is also efficacious for articular 
and cutaneous manifestations of SLE. 
The therapeutic dose of MTX ranges from 
7.5–20 mg/week and it is often prescribed 
with folic acid to lessen its mucositis 
adverse effects. MTX may potentially 
cause leukopenia and deranged liver 
function and, therefore, requires frequent 
monitoring in early commencement. If 
patients remain refractory to these medi-
cations, low-dose corticosteroids may be 
required for treatment.
The treatment goals in SLE include 
induction of remission and prevention 
of future relapses. Corticosteroids and 
immunosuppressive drugs are the 
mainstay of therapy for moderate to 
severe presentations of lupus, such as 
profound haematological involvement, 
serositis, lupus nephritis and nervous 
system involvement.1 Prednisolone 
0.5–1.0 mg/kg/day, or equivalent dose 
of other preparations of corticosteroids, 
are required at flares with moderate to 
severe manifestations. Pulse steroids, ie, 
methylprednisolone 500–1,000 mg daily 
for three consecutive days, are reserved 
for severe lupus presentations such as 
Class IV lupus nephritis with crescents, 
cerebritis and transverse myelitis. A 
number of immunosuppressive drugs 
have been used for many decades in 
lupus history, and more recently, some 
immunosuppressants, previously used 
in solid organ transplantation, have been 
shown to be efficacious in the treatment 
of active SLE. Table 1 highlights some 
common immunosuppressive drugs used 
in the treatment of SLE, their indications, 
recommended doses for local Chinese 
patients, and adverse effect profile.
Azathioprine is a common immuno- 
suppressive drug that has a steroid-
sparing effect, allowing gradual tapering 
of corticosteroids to a low maintenance 
dose for long-term use in the prevention of 
a flare. It is associated with bone marrow 
suppression presenting as megaloblastic 
anaemia and leukopenia. Thiopurinemeth-
yltransferase (TPMT) genotyping or TPMT 
activity measurement may be useful for 
the prediction of patients at risk of sig-
nificant myelosuppression, but is not 
cost-effective due to the low frequency 
of homozygous subjects who have very 
low TPMT activity.
Cyclophosphamide (CTX) is a 
cytotoxic drug and has been the gold 
standard for induction therapy in active 
lupus nephritis for many decades. CTX 
is also indicated for major central or 
peripheral nervous system involvement 
by lupus. CTX induction therapy can be 
prescribed as daily oral tablets or can be 
delivered as a monthly intravenous pulse 
dose both for 6 months. CTX induction 
therapy is associated with bone marrow 
suppression and increased risk of infection 
and requires close monitoring of white 
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blood cell count. This induction therapy 
by CTX is usually sequentially followed by 
azathioprine maintenance therapy. CTX 
may cause haemorrhagic cystitis which 
can be prevented by ample fluid intake 
and application of mesna prior to pulse 
therapy. A key concern for patients with 
SLE receiving CTX is the potential for 
premature ovarian failure. However, with 
the introduction of mycophenolate acid 
(MPA), which clinical studies have dem-
onstrated to be an effective induction and 
maintenance therapy in active Class III and 
IV lupus nephritis,2 this concern has been 
alleviated. MPA is an immunosuppressant 
with a suppressive effect on T and B lym-
phocytes implemented in the management 
of organ transplantation. Unlike CTX, MPA 
does not affect ovarian function, although 
its use during pregnancy is not recom-
mended. Mycophenolate mofetil (MMF) 
is a pro-drug of MPA with increased bio-
availability; however, it may be associated 
with gastrointestinal side effects, such as 
stomach upset and diarrhoea. Early clinical 
trials on the efficacy of MMF in patients 
with SLE excluded patients with active 
aggressive crescentic glomerulonephritis 
and did not include other major organ 
involvement as primary study endpoints. 
However, despite this, the clinical efficacy 
of MMF in other systemic manifestations 
of SLE has been widely reported. 
Cyclosporine (CSA) is an old-
fashioned immunosuppressive drug in 
the treatment of SLE. It is a calcineurin 
inhibitor and targets T lymphocytes. CSA 
is not widely used in lupus therapy as it is 
associated with adverse effects including 
hypertension, impaired renal function and 
hypertrichosis. It is considered in patients 
with SLE who have active diseases 
refractory to conventional therapy, such 
as significant thrombocytopenia and lupus 
nephritis. While concomitant diltiazem 
may be used to potentiate the immu-
nosuppressive effect of CSA, patients 
on CSA should avoid grapefruit juice as 
this inhibits its metabolism. Tacrolimus, 
another member of the calcineurin 
inhibitors class, has increasingly been 
reported to be useful in treating active 
lupus nephritis, but clinical data from ran-
domized controlled trials are still pending.
Family planning is an important 
aspect in the management of patients 
with SLE and concerns have been 
raised by patients with regards to the 
safety of immunosuppressive drugs 
during pregnancy. The FDA category 
in terms of ‘risk for pregnancy’ for the 
discussed immunosuppressants are 
shown in Table 1. Overall, hydroxychlo-
roquine, corticosteroids and azathioprine 
are generally safe during pregnancy 
but patients should be advised on con-
traception and postpone planning for 
pregnancy if they have recent history of 
active disease under treatment of other 
immunosuppressive drugs.3 While the 
use of prednisolone and azathioprine is 
not contraindicated in breastfeeding, the 
potential benefits of breastfeeding must 
be weighed against possible risk. 
Although immunosuppressive 
agents are effective treatment for active 
SLE in most patients, there remain 
issues such as refractory diseases and 
drug compliance. A number of biologic 
agents that target specific immune cells 
or soluble factors are currently under 
evaluation in clinical trials and may offer 
better treatment outcomes in patients 
with refractory conditions. Explanation 
of the clinical effectiveness and adverse 
effect profile to patients would help 
improve compliance. Moreover, the 
choice of immunosuppressive agents 
and the dosage prescribed also largely 
depends on concomitant comorbidities 
such as infective complications and 
impaired renal function. Importantly, the 
risk of infection and necessary preventive 
measures should be emphasized when 
commencing patients on immunosup-
pressive drugs.
table 1.common immunosuppressive drugs used in the treatment of SLe
medication   
(Route and dosage)
indication common side effects compatibility with 
pregnancy
compatibility with 
breastfeeding
Methotrexate
(p.o. 7.5–20 mg/week)
Articular and cutaneous 
manifestations
Leukopenia, nausea, vomiting, mucositis, 
deranged liver function, folate deficiency
Contraindicated Contraindicated
Azathioprine
(p.o. 2 mg/kg/day)
Steroid-sparing drug in 
moderate to severe disease
Bone marrow suppression, liver function 
derangement
Yes Yes (benefits may 
outweigh risks)
Cyclophosphamide
(p.o. 100 mg daily for 6 months or 
monthly intravenous pulse  
750 mg/m2 for 6 months)
Induction therapy for severe 
lupus nephritis and major 
nervous system involvement
Nausea, vomiting, bone marrow 
suppression, haemorrhagic cystitis, 
premature ovarian failure
Contraindicated Contraindicated
Mycophenolate mofetil (Cellcept®) 
(p.o. 1 g BD as induction, 1 g/day 
as maintenance)
Induction and maintenance 
therapy for lupus nephritis
Nausea, vomiting, diarrhoea, bone marrow 
suppression
Not recommended Not recommended
Myphenolate sodium (Myfortic)
(720 mg BD as induction, 720 mg 
daily as maintenance)
Induction and maintenance 
therapy for lupus nephritis
Nausea, vomiting, diarrhoea, bone marrow 
suppression
Not recommended Not recommended
Cyclosporine
(3–5 mg/kg/day)
Moderate to severe disease Renal impairment; hyperuricaemia, 
hypertension, headache, gum hypertrophy, 
hypertrichosis
Not recommended Not recommended
A complete list of references can be downloaded from 
www.SOPHYSICIANSHK.org
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many rheumatic diseases manifest as joint inflammation, for example, rheumatic arthritis 
(RA), a chronic systemic autoimmune 
arthritis which affects around 1% of the 
population. Without proper and timely 
treatment, persistent inflammation 
leads to cartilage damage, bone erosion 
and joint destruction. The introduction 
of synthetic DMARDs, such as metho-
trexate and sulphasalazine, has resulted 
in marked improvement in the control 
of arthritis. However, despite these 
medications, a significant proportion 
of patients continue to have persistent 
joint inflammation and progressive joint 
destruction. 
Over the past decade, biologic 
therapies have revolutionized the 
treatment of rheumatic diseases like RA, 
ankylosing spondylitis, psoriatic arthritis 
and juvenile inflammatory arthritis. 
Blocking signaling by tumour necrosis 
factor (TNF), a proinflammatory cytokine, 
has been a major target in tackling the 
underlying pathology of autoimmune 
diseases with biological molecules. 
Etanercept, a fully humanized TNF 
antagonist, was approved in 1998 as the 
first biologic therapy for the treatment 
of RA. Infliximab and adalimumab 
swiftly followed, and certolizumab pegol 
and golimumab were approved more 
recently.
Although TNF inhibitors have 
proven to be effective treatments for 
RA and other rheumatic conditions, a 
proportion of patients with RA do not 
respond, or achieve an optimal response, 
to TNF inhibition. Therefore, biologic 
agents that target other inflammatory 
pathways have also been developed. 
To date, agents targeting IL-1 (anakinra) 
and IL-6 pathways (tocilizumab), T-cell co-
stimulatory pathways (abatacept) and B 
cells (rituximab) have been approved for 
the treatment of moderate to severe RA, 
and other rheumatic conditions (Table 1).
As with any drug, safety concerns 
affect the choice and use of these 
agents. Several issues, such as the risk 
of infection, malignancy or infusion 
reactions, apply to all biological com-
pounds in this class. Other safety 
concerns, such as demyelinating disease, 
congestive heart failure, leucopenia and 
hyperlipidaemia, are associated with indi-
vidual biologic agents and there are some 
conditions that affect patient selection 
and management that are specific to 
certain biologic treatments. 
Infections
It is well recognized that patients with 
RA are at an increased risk of infection, 
and while biologic therapies are effective 
in achieving disease control in RA, inter-
ference in the innate or adaptive immune 
system presents a further increased risk 
of infection and potential reactivation of 
latent infection. This remains one of the 
main safety concerns of these therapies. 
TNF signaling is crucial in recog-
nizing and responding to infection. As 
the use of the TNF inhibitors increases, 
data regarding serious bacterial infections 
have been collected in several large reg-
istries and databases. Analyses of these 
data have revealed an increased risk of 
infections with the three anti-TNF agents, 
particularly in the first 6 months of 
treatment (adjusted hazard ratio [HR]: 1.8; 
95% CI: 1.3–2.6).1 In addition, increased 
rates of pneumonia have been noted 
within the first 6 months,2 suggesting the 
first 6 months is the period of greatest 
risk.  
TNF inhibitors are not the only bio-
logical agents to cause increased risk 
of infections; tocilizumab, a humanized 
antibody to the IL-6 receptor, disrupts IL-6 
signaling. Infection rates in patients with 
RA treated with tocilizumab are similar 
to those in patients treated with TNF 
inhibitors. A meta-analysis of abatacept in 
RA has shown that the increase in serious 
infections following treatment was not 
statistically significant; this finding was 
supported by a Cochrane review of 
abatacept use for all indications.4 
Randomized controlled trials (RCTs) 
of rituximab in patients with RA have 
reported higher rates of serious infection 
with rituximab than with control, but the 
differences were not statistically sig-
nificant.6 This was further demonstrated 
by a meta-analysis of three RCTs.4, 6, 7
Tuberculosis reactivation
It is known that TNF plays an essential 
role in defence against Mycobacterium 
tuberculosis and other intracellular 
bacterial and fungal pathogens. Early 
Risks and Benefits of Biologic agents  
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reports of tuberculosis (TB) reactivation 
have provided insights into the role of 
TNF in granuloma stabilization in animal 
models.8 Several registries and retro-
spective studies9 have confirmed the 
increased incidence of TB in patients with 
RA receiving anti-TNF compared with the 
general population and with patients with 
RA not receiving anti-TNF. A local study at 
five centres in Hong Kong analyzed 2,441 
patients with RA and found that the stan-
dardized incidence ratio (SIR) of active 
TB in RA was significantly increased (SIR 
for TNF-naïve RA: 2.35, 95% CI: 1.17–
4.67, p=0.013, SIR for TNF-treated RA: 
34.92, 95% CI: 8.89–137.20, p<0.001).9 
Older age, a past history of pulmonary 
TB, Felty’s syndrome and steroid use 
have been documented as independent 
variables associated with an increased 
risk of active TB.9 The introduction of 
screening and prophylaxis for latent TB 
infection before the initiation of anti-TNF 
therapy has been shown to reduce the 
risk of TB reactivation.10 Fewer data are 
available for the newer biologics.
Hepatitis B reactivation
Immune suppression has been asso-
ciated with hepatitis B virus (HBV) reac-
tivation in chronic carriers. Patients 
with resolved hepatitis B infection may 
develop recurrent hepatitis B infection 
leading to fulminant hepatic failure and 
death. Administration of anti-TNF agents 
and rituximab has been associated with 
the reactivation of HBV. For patients 
receiving TNF inhibitors, hepatic failure 
is more likely to occur in those who are 
actively infected, rather than in chronic 
carriers. There have, however, been case 
reports of fatal outcome due to HBV 
reactivation following infliximab admin-
istration in patients with chronic HBV. 
A meta-analysis identified 257 patients 
with reported  hepatitis B treated with 
anti-TNF agents, with a significant per-
centage of liver damage in HBV surface 
antigen (HBsAg) carriers, including raised 
transaminase levels (42%), signs and 
symptoms of liver disease (16%), reap-
pearance of serum HBV-DNA (39%) and 
death related to liver failure (5%).11 
Reactivation of occult hepatitis B 
infection (HBsAg negative but hepatitis B 
core antibody positive) has been reported 
in the oncology literature12 and several 
case reports were published on patients 
with RA treated with rituximab, however, 
there are less data on patients treated 
with tocilizumab. Chronic HBV infection 
need not preclude biologic therapy; use 
of anti-TNF and biologics may generally 
be considered with careful counseling 
and intensive monitoring.
Malignancies
Conflicting evidence exists regarding the 
risk of malignancies; a meta-analysis of 
RCTs of infliximab or adalimumab sug-
gested that higher doses of anti-TNF 
may be associated with an increased 
risk of malignancy, in comparison with 
lower doses.13 However, a meta-analysis 
of clinical registries and prospective 
observational studies identified no 
increase in malignancies other than skin 
cancers, associated with the use of TNF 
inhibitors.14 Regardless of treatment, 
patients with RA, or other autoimmune 
diseases, are at higher risk of developing 
malignancies compared to the general 
population.15 For example, patients with 
RA have a higher risk of lung cancer and 
lymphoma; the risk of lymphoma seems 
to correlate with disease activity.16 
Conclusion
Biologic agents directed at TNF-alpha, T-cell 
co-stimulation, B-cells, and IL 6 are effi-
cacious in clinical trials for the treatment 
of RA patients with an inadequate 
response to conventional DMARDs. 
Evidence has shown that these biologic 
agents can delay radiographic pro-
gression. That means, in addition to the 
reduction of short-term disability from 
symptoms of inflammatory arthritis, 
biologic agents are beneficial in pre-
venting long-term disability from joint 
damage. Therefore, the biologic agents 
are important tools for the treatment of 
rheumatic diseases. When used judi-
ciously, they are effective and relatively 
safe. However, patients being prescribed 
these agents should be carefully followed 
by physicians in view of possible serious 
adverse effects. By combining conven-
tional DMARDs and biologic agents, the 
management of rheumatic diseases has 
been transformed over the past 10 years 
offering patients with rheumatic diseases 
great hope that they will experience 
clinical benefits and maintain functional 
and happy lives.
table 1 Biologic agents for the treatment of Ra
medications target Route of 
administration
maintenance dose
Infliximab TNF-alpha intravenous 3–10 mg/kg every 4–8 weeks
Etanercept TNF-alpha subcutaneous 50 mg weekly
Adalimumab TNF-alpha subcutaneous 40 mg monthly
Certolizumab TNF-alpha subcutaneous 200 mg fortnightly
Or 400 mg monthly
Golimumab TNF-alpha subcutaneous 50 mg monthly
Abatacept T-cell costimulation intravenous 500–1,000 mg every 4 weeks
Rituximab CD20+ B cells intravenous 2 separate 1,000 mg doses 2 weeks 
apart every 6 months
Tocilizumab IL-6 receptor intravenous 4–8 mg per kg every 4 weeks
Anakinra IL-1 receptor subcutaneous 100 mg daily
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Introduction
Since the discovery of salicylate in 
1763, over 250 years ago, there has 
been tremendous development which 
has resulted in a large family of medi-
cation, namely, NSAIDs. These have a 
wide spectrum of clinical indications, 
from treating short-term acute pain like 
dysmenorrhoea and acute dental pain 
to chronic conditions including degen-
erative and inflammatory joint diseases. 
It has been estimated that over 17 million 
Americans receive NSAIDs on a daily 
basis; this is not surprising as NSAIDs are 
commonly prescribed across many dif-
ferent specialties. This article will review 
this class of medication, with a particular 
focus on those areas that not commonly 
discussed.
classifications of NSaIDs
Over the past two decades, delineating 
and distinguishing COX selectivity to 
categorize different NSAIDs has been 
emphasized. The selectivity of COX-1 and 
COX-2 will be elaborated further, but it 
should be noted that there are different 
chemical classes within this large family 
(Table 1).
The different chemical classes 
are of particular relevance for patients 
failing therapy, as it would be rational 
to switch to another agent from a dif-
ferent chemical class. Chemical classes 
are also of relevance for patients with 
a prior history of allergy, agents with 
a sulphonamide-moiety, as in case of 
celecoxib, should be avoided in patients 
with prior history of sulphonamide 
allergy. Previously, a non-acidic agent 
(nabumatone) claimed to have a theo-
retical advantage over weak acids with 
regards to gastric mucosal irritation, 
as a strongly acidic environment could 
trap weakly acidic NSAIDs in a mucosal 
microenvironment.
Chemical class aside, these agents 
can also be grouped according to the 
duration of half-life, into short-acting 
(diclofenac, ibuprofen, indomethacin) 
or long-acting (celecoxib, meloxicam, 
naproxen, nabumetone) therapies. Dif-
ferent routes of administration also 
provide clinicians with flexibility in pre-
scribing NSAIDs under different clinical 
scenarios, perhaps where oral admin-
istration is either unfeasible or unfa-
vourable.
Mechanism of action and 
efficacy
Inhibition of cyclo-oxygenase
The main mechanism of action that 
accounts for the clinical efficacy of 
NSAIDs is the inhibition of cyclo-oxy-
genases (COX-2 and COX-1); this in turn 
affects the conversion of arachidonic 
acid into various prostaglandin related 
products (PGG2, PGH2, PGD2, PGE2, 
PGI2 and TXA2). 
COX-1, a constitutive form, 
maintains important physiologic 
functions, whereas, COX-2, an inducible 
form, is produced as a response to 
an inflammatory state. However, one 
should note that COX-2 is constitutively 
expressed in brain, kidney, bone and the 
female reproductive system. The anti-
inflammatory mode of action of NSAIDs 
is due to the inhibition of COX-2.
Non-prostaglandin mediated 
effects
NSAIDs may be inserted into biological 
membranes and disrupt interactions, 
for example, NSAIDs decrease the 
expression of L-selectin which is critical 
for migration of neutrophils to sites of 
inflammation. An in vitro study has de-
monstrated that NSAIDs inhibit NF-kB 
and consequently inhibit TNF-alpha and 
inducible nitric oxide synthetase (iNOS). 
Selective cox-2 inhibitors and  
non-Selective nSaiDs: a Recap
table 1
chemical class example
Salicylate (acetylated) Aspirin
Salicylate (non-acetylated) Diflunisal, salsalate
Propionic acids Ibuprofen, naproxen, ketoprofen
Acetic acid Diclofenac, etodolac, indomethacin, sulindac
Oxicams (enolic acid) Piroxicam, meloxicam
Fenamates (antranilic acid) Mefenamic acid, meclofenamate
Nonacidic (naphthylalkanone) Nabumetone
Selective COX-2 inhibitor Celecoxib, etoricoxib
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An impact on apoptosis and an anti-prolif-
erative effect has been demonstrated by 
NSAIDs that cannot be entirely explained 
by the inhibition of prostaglandin syn-
thesis. The anti-proliferative effect of 
NSAIDs provides the rationale for their 
use in reducing the development of 
colonic adenomas.
Clinical indications  
(Table 2)
NSAIDs have anti-inflammatory effects 
in various inflammatory musculoskeletal 
disorders, for example, in acute gout 
attack, persistent inflammatory arthritides 
(rheumatoid arthritis, arthritis spondylitis 
and psoriatic arthritis), and soft-tissue 
inflammation (bursitis, tendinitis). Some 
NSAIDs have an indication for ‘pain’, and 
trials have been conducted in the context 
of post-operative pain control, acute 
dental pain and dysmenorrhoea. NSAIDs 
may be used in combination with other 
modalities for the control of cancer pain.
Adverse effects and 
precautions
Gastrointestinal: 
As COX-1 maintains gastrointestinal (GI) 
mucosal integrity, NSAIDs can cause GI 
adverse effects due to its inhibition. This 
can be avoided by using specific COX-2 
inhibitors; the use of a proton pump 
inhibitor is an alternative measure but it 
cannot tackle the damage to small bowel 
and large intestinal mucosa.
Cardiovascular: 
NSAIDs may cause water retention, 
increased hypertension and deterioration 
for patients with congestive heart failure. 
The association of a cardiovascular event, 
which was initially thought to be related 
to the use of a specific COX-2 inhibitor, 
has also been shown to occur when using 
non-naproxen non-selective NSAIDs.
Renal: 
Water and electrolyte disturbance (hypo-
natriaemia and hyperkalaemia) have been 
reported. Patients with pre-existing renal 
impairment should be monitored for acute 
deterioration of renal function. Other 
NSAIDs-related kidney problems include 
nephrotic syndrome, chronic interstitial 
nephritis and papillary necrosis.
Haematology: 
Anti-platelet action has been seen to 
occur with non-selective NSAIDs (this, 
however, does not occur with COX-2 
inhibitors, as there is an absence of 
COX-2 activity in platelets). Therefore, 
one may consider withholding NSAIDs 
pre-operatively for approximately 3 days 
(four to five times the drug half-life) prior 
to surgery (some studies have shown 
that 1 day is sufficient for an ibuprofen 
user). Neutropenia is an uncommon 
(<1%) adverse effect of NSAIDs use.
Pulmonary: 
Bronchospasm (in some case due to inhi-
bition of COX-1) and pulmonary infiltrates 
with eosinophilia have been described, 
though the incidence of these events is 
not known.
Hepatic dysfunction: 
A few years ago, the media reported the 
extremely rare occurrence of using topical 
NSAIDs resulting in hepatic damage. This 
caused major concern for patients and, 
as a result, there are currently patients 
declining the appropriate use of NSAIDs. 
The biochemical elevation of transaminase 
without clinical hepatitis has been seen 
to occur; in a large retrospective study 
of 625,000 patients, the incidence of 
acute liver injury was 3.7 per 100,000. 
Treatment with sulindac increased the 
incidence to 27 per 100,000, which is 
still very rare. Transient minor increases 
in transaminase have not been useful for 
predicting the subsequent occurrence of 
acute liver damage. Therefore, patients 
should be properly advised on this issue.
Central nervous system: 
Cognitive impairment and psychosis 
have been found, especially in geriatric 
patients using indomethacin. There is an 
association of aseptic meningitis among 
patients with lupus using NSAIDs from 
the phenyl propionic acid group (ibu-
profen and naproxen). Patients using 
non-salicylate NSAIDs occasionally suffer 
from tinnitus.
Cutaneous reaction: 
Both morbilliform rash and urticaria can 
be related to the use of NSAIDs. Toxic 
epidermal necrolysis and Steven-Johnson 
syndrome are severe but rare compli-
cations also associated with the use of 
NSAIDs, particularly the oxicam class; the 
estimated risk is very low at 1 per 100,000 
patients over 8 weeks of therapy.
Prescribing NSaIDs in 
clinical practice
A comprehensive patient assessment 
should be undertaken to minimize the risk 
when prescribing NSAIDs. Risk factors 
for NSAIDs-induced gastropathy (Table 
3) or those factors that may predispose 
patients toward acute renal impairment 
(Table 4) should be assessed. Comor-
bidities, such as congestive heart failure, 
hypertension, and asthma with sub-
optimal control, are factors that should 
encourage the consideration of another 
therapeutic class before using NSAIDs.
table 2
organ system/specialty indications
Cardiovascular IHD (aspirin)
Neurological Prevention of ischemic stroke (aspirin); migraine, headache
Musculoskeletal Arthritis, soft tissue inflammation (bursitis, tendinitis), trauma
Gastroenterology (Reduction of colonic adenoma)
Gynecological Dysmenorrhoea
Surgical Post-operative pain
Dental Dental pain
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Old age is related to a higher risk of 
various NSAID-related complications, for 
example, gastropathy, renal impairment 
and cognitive changes. Therefore, the 
American Geriatric Society has recom-
mended avoidance of NSAIDs use in pain 
management for patients over 75 years 
of age.
The possibility of combining dif-
ferent therapeutic classes of analgesics 
should be considered rather than pre-
scribing patients high-dose NSAIDs. It 
is good practice to keep the dosage of 
NSAID at the lowest possible effective 
dosage and for a limited duration (the 
shorter the better).
Patients should be properly 
educated regarding the use of NSAIDs, as 
with all medications. Clinicians and other 
healthcare professionals should not alarm 
patients by using examples of rare compli-
cations or special clinical case scenarios, 
instead, patients should be properly 
guided by well-balanced information.
Patients should be educated that 
different painful conditions can arise from 
various mechanisms, such as angina 
due to underlying myocardial ischaemia, 
or epigastric pain due to peptic ulcer 
disease. Patients should be made aware 
that although NSAIDs can be used as an 
analgesic, it will not be an appropriate 
treatment for all painful medical con-
ditions.
Conclusion
NSAIDs are commonly prescribed, as 
both an effective anti-inflammatory agent 
and an analgesic option; they play an 
important role in managing patients on a 
daily basis. Although NSAIDs are known 
to be associated with various adverse 
effects, the risks can be minimized if a 
proper patient assessment has been con-
ducted. As a medication that has been 
used in the medical field for over 250 
years, we still need to better understand 
their mechanism of action in order to 
achieve a better and safer outcome for 
our patients.
table 4
Risk factors for nSaiDs-related acute 
kidney injury
•	Old age
•	Pre-existing renal impairment
•	Renal artery stenosis
•	Nephrotic syndrome
•	Dehydration and volume depletion
•	Congestive heart failure
•	Cirrhosis
•	Co-administrated medications: diuretics, 
ACE-I, angiotensin receptor blocker, 
calcineurin inhibitors
table 3
Risk factors for nSaiDs-related 
gastropathy
•	Age >65
•	History of peptic ulcer
•	High dose of NSAIDs used
•	Co-administrating medications: moderate-to 
high dose steroid, anticoagulant, aspirin
ThE SocIETY oF PhYSIcIaNS oF hoNG KoNG
UPCOMING EVENTS
 may 18, 2014 Sunday Symposium  the Langham hotel, tSt
 June 13, 2014 friday Lunch and lecture at hKma in central
 July 6, 2014 Sunday Symposium  the Langham hotel, tSt
 July 20, 2014 Sunday Symposium   the Langham hotel, tSt
Programme subject to change
Please see updated information on the Web
www.SoPhySicianShK.org
CM
Y
CM
MY
CY
CMY
K
Cel206x275(2014).pdf   1   21/2/14   3:19 PM

JSPHK Mar 2014 issue 
Page 19 – Glucocorticoid Use in Rheumatology: Mechanism of Action, Adverse Effects and Guidance on Monitoring  
                   Dr Chau Shuk Yi, Lucia (周淑儀醫生) 
 
References: 
 
1. Carryer HM, Koelsche GA, Prickman LE, et al. Effects of cortisone on bronchial asthma and hay fever occuring 
in subjects sensitive to ragweed pollen. Proc Staff Meet Mayo Clin 1950;25: 482-486. 
2. Turk Rheun, John A, Cidlowski. Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N 
Engl J Med 2005;353:1711-1723. 
3. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharm Ther 
2002;96:23-43.  
4. Kawai K, Tamaki A, Hirohata K. Steroid-induced accumulation of lipid in the osteocytes of the rabbit femoral 
head. A histochemical and electron microscopic study. J Bone Joint Surg Am. Jun 1985;67(5):755-763. 
5. Aaron RK, Voisinet A, Racine J, et al. Corticosteroid-associated avascular necrosis: dose relationships and early 
diagnosis. Ann N Y Acad Sci 2011;1240:38-46. 
6. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced 
osteoporosis. J Bone Miner Res 1999;14(7):1061-1066. 
7. Pearce G, Ryan PFJ, Delmas PD, et al. The deleterious effects of low-dose corticosteroids on bone density in 
patients with polymyalgia rheumatic. Br J Rheumatol 1998;37:292-299. 
8. Reid IR. Glucocorticoid-induced osteoporosis. Baillieres Clin Endocrinol Metab 2000;14(2):279 -298. 
9. Piper JM, Ray WA, Daugherty JR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-
inflammatory drugs. Ann Intern Med 1991;11:735-740. 
10. Carson JL, Strom BL, Schinnar R, et al. The low risk of upper gastrointestinal bleeding in patients dispensed 
corticosteroids. Am J Med 1991;91:223-228. 
11. Van der Goes MC, Jacobs JWG, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: 
EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69(11):1913-1919. 
12. Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations 
on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 
2013;72(12):1905-1913. 
 
JSPHK Mar 2014 issue 
Page 22 – Fibromyalgia  
                   Dr Lee Tsz Yan, Samson (李梓恩醫生) 
 
References: 
 
1. Carette S: Fibromyalgia 20 years later: what have we really accomplished (editorial)? J Rheumatol 
1995;22:590-594. 
2. Goldenberg D: Fibromyalgia: why such controversy? Ann Rheum Dis 1995;54:3-5. 
3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the 
classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172. 
4. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general 
population. Arthritis Rheum 1995;38:19-28. 
5. Buskila D, Neumann L, Sibirski D, Shvartzman P. Awareness of diagnostic and clinical features of fibromyalgia 
among family physicians. Fam Pract 1997;14:238-41. 
6. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic 
criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62(5):600-
10. 
7. Yunus MB, Inanici F, Aldag JC, Mangold RF. Fibromyalgia in men: comparison of clinical features with women. 
J Rheumatol. 2000;27:485-490. 
8. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the 
general population. Arthritis Rheum 1995;38(1):19-28. 
9. Buchwald D, Umali P, Umali J, Kith P, Pearlman T, Komaroff AL. Chronic fatigue and the chronic fatigue 
syndrome: prevalence in a Pacific Northwest health care system. Ann Intern Med 1995;123(2):81-8. 
10. Pawlikowska T, Chalder T, Hirsch SR, Wallace P, Wright DJ, Wessely SC. Population based study of fatigue and 
psychological distress. BMJ 1994;308(6931):763-766. 
11. Santos AM, Burti JS, Lopes JB, Scazufca M, Marques AP, Pereira RM. Prevalence of fibromyalgia and chronic 
widespread pain in community-dwelling elderly subjects living in São Paulo, Brazil. Maturitas 2010;67(3):251-
5. 
12. Wigley et al, Rheumatic diseases in China: ILAR-China study comparing the prevalence of rheumatic 
symptoms in northern and southern rural populations. The Journal of Rheumatology 1994;21(8):1484-1490. 
13. Roger A. Scudds, Edmund K-M. Li, Rhonda J. The Prevalence of Fibromyalgia Syndrome in Chinese People in 
Hong Kong Journal of Musculoskeletal Pain 2006;14(2):3-11. 
14. Palstam A, Bjersing JL, Mannerkorpi K. Which aspects of health differ between working and nonworking 
women with fibromyalgia? A cross-sectional study of work status and health. BMC Public Health 
2012;12:1076. 
15. Dreyer L, Kendall S, Danneskiold-Samsoe B, Bartels EM, Bliddal H. Mortality in a cohort of Danish patients 
with fibromyalgia: increased frequency of suicide. Arthritis Rheum 2010;62(10):3101-3108. 
16. Palstam A, Bjersing JL, Mannerkorpi K. Which aspects of health differ between working and nonworking 
women with fibromyalgia? A cross-sectional study of work status and health. BMC Public Health 
2012;12:1076. 
17. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of 
fibromyalgia. Arthritis Rheum 1997;40(11):1928-1939. 
18. van Middendorp H, Lumley MA, Jacobs JW, Bijlsma JW, Geenen R. The effects of anger and sadness on clinical 
pain reports and experimentally-induced pain thresholds in women with and without fibromyalgia. Arthritis 
Care Res (Hoboken) 2010;62(10):1370-1376. 
19. Martinez-Lavin M. Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia. 
Arthritis Res Ther 2007;9(4):216. 
20. Tanriverdi F, Karaca Z, Unluhizarci K, et al. The hypothalamo-pituitary-adrenal axis in chronic fatigue 
syndrome and fibromyalgia syndrome. Stress 2007;10(1):13-25. 
21. Staud R, Robinson ME, Vierck CJ Jr, et al. Diffuse noxious inhibitory controls (DNIC) attenuate temporal 
summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain 
2003;101(1-2):167-174. 
22. Burckhardt CS. Multidisciplinary approaches for management of fibromyalgia. Curr Pharm Des 2006;12(1):59-
66. 
JSPHK Mar 2014 issue 
Page 22 – Fibromyalgia  
                   Dr Lee Tsz Yan, Samson (李梓恩醫生) 
23. Sarzi-Puttini P, Buskila D, Carrabba M, et al. Treatment strategy in fibromyalgia syndrome: where are we now? 
Semin Arthritis Rheum 2008;37(6):353-365. 
24. S F Carville et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. 
Ann Rheum Dis 2008;67:4 536-541 Published Online First: 20 July 2007. 
25. Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol. Mar 2007;19(2):111-117. 
26. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, 
doubleblind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 
2002;112:191–197. 
27. Winfield JB. Pain and arthritis. N C Med J. 2007;68(6):444-446. 
JSPHK Mar 2014 issue 
Page 25 – Immunosuppressants in Systemic Lupus Erythematosus – Treatment Options and Potential Toxicity  
                   Dr Mok Mo Yin, Temy (莫慕賢醫生) 
 
References: 
 
1. Kiriakidou M, Cotton D, Taichman D, Williams S. Systemic lupus erythematosus. Ann Intern Med 2013 Oct 
1:159(7):ITC4-1. Doi:10.7326/0003-4819-159-7-201310010-01004 
2. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Hong Kong Nephrology Study Group. Long-term study of 
mycophenolatemofetil as continuous induction and maintenance treatment for diffuse proliferative lupus 
nephritis. J Am SocNephrol 2005;16:1076–1084. 
3. Bermas BL. Use of anti-inflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy 
and lactation. In: UpToDate, Romain PL(Ed), UpToDate, Waltham, MA, 2014  
 
